

Matthew A Powell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6702928/publications.pdf>

Version: 2024-02-01

93
papers

2,331
citations

236925

25
h-index

243625

44
g-index

96
all docs

96
docs citations

96
times ranked

3112
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 2317-2326.	27.0	326
2	Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). <i>Journal of Clinical Oncology</i> , 2020, 38, 3841-3850.	1.6	155
3	Phase II Evaluation of Paclitaxel and Carboplatin in the Treatment of Carcinosarcoma of the Uterus: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 2727-2731.	1.6	151
4	An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. <i>Gynecologic Oncology</i> , 2018, 148, 174-180.	1.4	83
5	A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2014, 135, 38-43.	1.4	82
6	Postoperative Radiation Therapy for Endometrial Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline. <i>Journal of Clinical Oncology</i> , 2015, 33, 2908-2913.	1.6	76
7	Evaluation of Ovarian Cancer: Initial Application of Coregistered Photoacoustic Tomography and US. <i>Radiology</i> , 2018, 289, 740-747.	7.3	60
8	Ribosomal DNA methylation in patients with endometrial carcinoma. <i>Cancer</i> , 2002, 94, 2941-2952.	4.1	58
9	Intensity Modulated Radiation Therapy and Image-Guided Adapted Brachytherapy for Cervix Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 1088-1097.	0.8	57
10	FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival. <i>Gynecologic Oncology</i> , 2020, 157, 639-643.	1.4	57
11	Second-line lenvatinib in patients with recurrent endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 156, 575-582.	1.4	53
12	Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol. <i>Gynecologic Oncology</i> , 2017, 145, 519-525.	1.4	52
13	Impact of an immunohistochemistry-based universal screening protocol for Lynch syndrome in endometrial cancer on genetic counseling and testing. <i>Gynecologic Oncology</i> , 2015, 137, 7-13.	1.4	47
14	Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer. <i>British Journal of Cancer</i> , 2018, 118, 72-78.	6.4	46
15	A phase II evaluation of AMG 102 (rilatumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2014, 132, 526-530.	1.4	40
16	FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 145, 366-373.	1.4	40
17	Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 968-977.	1.6	38
18	Intensity modulated radiation therapy for recurrent ovarian cancer refractory to chemotherapy. <i>Gynecologic Oncology</i> , 2016, 141, 134-139.	1.4	37

#	ARTICLE	IF	CITATIONS
19	Phase II study of aximogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2020, 158, 562-569.	1.4	35
20	Brachytherapy Is Associated With Improved Survival in Inoperable Stage I Endometrial Adenocarcinoma: A Population-Based Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 649-657.	0.8	34
21	Improved survival with definitive chemoradiation compared to definitive radiation alone in squamous cell carcinoma of the vulva: A review of the National Cancer Database. <i>Gynecologic Oncology</i> , 2017, 146, 572-579.	1.4	34
22	Intensity modulated radiation therapy for squamous cell carcinoma of the vulva: Treatment technique and outcomes. <i>Advances in Radiation Oncology</i> , 2017, 2, 148-158.	1.2	33
23	Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 389-398.	4.1	32
24	Preparedness of Ob/Gyn residents for fellowship training in gynecologic oncology. <i>Gynecologic Oncology Reports</i> , 2015, 12, 55-60.	0.6	31
25	Phase I Trial of Stereotactic MRI-Guided Online Adaptive Radiation Therapy (SMART) for the Treatment of Oligometastatic Ovarian Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 379-389.	0.8	28
26	Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2881-2891.	4.1	27
27	Adult Comorbidity Evaluation 27 score as a predictor of survival in endometrial cancer patients. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 766.e1-766.e9.	1.3	23
28	Impact of molecular profiling on overall survival of patients with advanced ovarian cancer. <i>Oncotarget</i> , 2016, 7, 19840-19849.	1.8	23
29	Benefit of combination chemotherapy and radiation stratified by grade of stage IIIc endometrial cancer. <i>Gynecologic Oncology</i> , 2017, 147, 309-314.	1.4	22
30	Targeted metabolomic profiling of low and high grade serous epithelial ovarian cancer tissues: a pilot study. <i>Metabolomics</i> , 2018, 14, 154.	3.0	22
31	Recent advances in the treatment of sarcomas in gynecology. <i>Discovery Medicine</i> , 2014, 18, 133-40.	0.5	22
32	A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND#) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 who are in second or third complete remission: An NRG Oncology/GOG study. <i>Gynecologic Oncology</i> , 2019, 155, 393-399.	1.4	20
33	Adjuvant radiotherapy in Stage II endometrial carcinoma: Is brachytherapy alone sufficient for local control?. <i>Brachytherapy</i> , 2015, 14, 427-432.	0.5	19
34	ADXS11-001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: Results from stage I of the phase II GOG/NRG0265 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5516-5516.	1.6	19
35	GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress. <i>Molecular Cancer Research</i> , 2022, 20, 265-279.	3.4	19
36	Patterns of care, predictors, and outcomes of chemotherapy in elderly women with early-stage uterine carcinosarcoma: A population-based analysis. <i>Gynecologic Oncology</i> , 2014, 133, 242-249.	1.4	18

#	ARTICLE	IF	CITATIONS
37	Optical Resolution Photoacoustic Microscopy of Ovary and Fallopian Tube. <i>Scientific Reports</i> , 2019, 9, 14306.	3.3	17
38	Role of blood oxygenation saturation in ovarian cancer diagnosis using multi-spectral photoacoustic tomography. <i>Journal of Biophotonics</i> , 2021, 14, e202000368.	2.3	16
39	Adenovirus platform enhances transduction efficiency of human mesenchymal stem cells: An opportunity for cellular carriers of targeted TRAIL-based TR3 biologics in ovarian cancer. <i>PLoS ONE</i> , 2017, 12, e0190125.	2.5	14
40	A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 136, 94-98.	1.4	12
41	Association of post-treatment positron emission tomography with locoregional control and survival after radiation therapy for squamous cell carcinoma of the vulva. <i>Radiotherapy and Oncology</i> , 2017, 122, 445-451.	0.6	12
42	Quantitative multispectral ex vivo optical evaluation of human ovarian tissue using spatial frequency domain imaging. <i>Biomedical Optics Express</i> , 2018, 9, 2451.	2.9	12
43	Gynecologic Oncologists' Perceptions of Palliative Care and Associated Barriers: A Survey of the Society of Gynecologic Oncology. <i>Gynecologic and Obstetric Investigation</i> , 2019, 84, 50-55.	1.6	12
44	Assessing Physician Adherence to Guidelines for Cervical Cancer Screening and Management of Abnormal Screening Results. <i>Journal of Lower Genital Tract Disease</i> , 2020, 24, 337-342.	1.9	12
45	Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic via hierarchical binding events at the plasma membrane. <i>Oncotarget</i> , 2016, 7, 31534-31549.	1.8	12
46	Synuclein β in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study. <i>Cancer</i> , 2017, 123, 1144-1155.	4.1	11
47	Histogram analysis of en face scattering coefficient map predicts malignancy in human ovarian tissue. <i>Journal of Biophotonics</i> , 2019, 12, e201900115.	2.3	11
48	Continuous epidural infusion in gynecologic oncology patients undergoing exploratory laparotomy: The new standard for decreased postoperative pain and opioid use. <i>Gynecologic Oncology</i> , 2019, 153, 356-361.	1.4	11
49	Modified frailty index is predictive of wound complications in obese patients undergoing gynecologic surgery via a midline vertical incision. <i>Gynecologic Oncology</i> , 2020, 157, 287-292.	1.4	11
50	Which patients with inoperable vulvar cancer may benefit from brachytherapy in addition to external beam radiation? A Surveillance, Epidemiology, and End Results analysis. <i>Brachytherapy</i> , 2017, 16, 831-840.	0.5	10
51	Endometrial adenocarcinoma in the setting of a germline DICER1 mutation: A case report. <i>Gynecologic Oncology Reports</i> , 2017, 20, 121-124.	0.6	10
52	The effect of a multidisciplinary palliative care initiative on end of life care in gynecologic oncology patients. <i>Gynecologic Oncology</i> , 2017, 147, 460-464.	1.4	10
53	Risk of cervical and vaginal dysplasia after surgery for vulvar intraepithelial neoplasia or cancer: A 6-year follow-up study. <i>Gynecologic Oncology</i> , 2019, 155, 88-92.	1.4	10
54	Clinical outcomes after isolated pelvic failure in cervical cancer patients treated with definitive radiation. <i>Gynecologic Oncology</i> , 2019, 153, 530-534.	1.4	10

#	ARTICLE	IF	CITATIONS
55	Long-term outcomes of intensity-modulated radiation therapy (IMRT) and high dose rate brachytherapy as adjuvant therapy after radical hysterectomy for cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1157-1161.	2.5	10
56	The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women. <i>Gynecologic Oncology</i> , 2021, 160, 660-668.	1.4	9
57	Text-message-based behavioral weight loss for endometrial cancer survivors with obesity: A randomized controlled trial. <i>Gynecologic Oncology</i> , 2021, 162, 770-777.	1.4	9
58	New Treatments for Recurrent Uterine Cancer. <i>Current Oncology Reports</i> , 2021, 23, 139.	4.0	9
59	Society of Gynecologic Oncology Future of Physician Payment Reform Task Force report: The Endometrial Cancer Alternative Payment Model (ECAP). <i>Gynecologic Oncology</i> , 2018, 149, 232-240.	1.4	8
60	Impact of tumor histology on detection of pelvic and para-aortic nodal metastasis with ¹⁸ F-fluorodeoxyglucose-positron emission tomography in stage IB cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1351-1354.	2.5	8
61	Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study. <i>Gynecologic Oncology</i> , 2020, 156, 131-139.	1.4	8
62	Incorporation of Porcine Adenovirus 4 Fiber Protein Enhances Infectivity of Adenovirus Vector on Dendritic Cells: Implications for Immune-Mediated Cancer Therapy. <i>PLoS ONE</i> , 2015, 10, e0125851.	2.5	7
63	Development of a technique to detect the activated form of the progesterone receptor and correlation with clinical and histopathological characteristics of endometrioid adenocarcinoma of the uterine corpus. <i>Gynecologic Oncology</i> , 2015, 138, 663-667.	1.4	7
64	A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 144, 101-106.	1.4	7
65	Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer®-accredited facilities. <i>Gynecologic Oncology</i> , 2020, 157, 121-130.	1.4	7
66	Impact of the COVID-19 pandemic on referral to and delivery of gynecologic oncology care. <i>Gynecologic Oncology Reports</i> , 2022, 39, 100928.	0.6	7
67	Membrane-proximal TRAIL species are incapable of inducing short circuit apoptosis signaling: Implications for drug development and basic cytokine biology. <i>Scientific Reports</i> , 2016, 6, 22661.	3.3	6
68	Repeating platinum/bevacizumab in recurrent or progressive cervical cancer yields marginal survival benefits. <i>Gynecologic Oncology Reports</i> , 2017, 22, 48-51.	0.6	6
69	Patients with endometrial cancer continue to lack understanding of their risks for cancer. <i>Gynecologic Oncology Reports</i> , 2019, 29, 106-110.	0.6	6
70	Do gynecologic oncology patients with severely diminished renal function and urinary tract obstruction benefit from ureteral stenting or percutaneous nephrostomy?. <i>Gynecologic Oncology Reports</i> , 2019, 28, 136-140.	0.6	6
71	GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2019, 153, 335-342.	1.4	6
72	Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2020, 159, 79-87.	1.4	6

#	ARTICLE	IF	CITATIONS
73	State of the science: Uterine sarcomas: From pathology to practice. <i>Gynecologic Oncology</i> , 2020, 159, 3-7.	1.4	6
74	Impact of employment and insurance status on distress in gynecologic oncology patients. <i>Gynecologic Oncology</i> , 2021, 161, 477-482.	1.4	6
75	Factors influencing residents'™ interest in gynecologic oncology fellowship. <i>Gynecologic Oncology Reports</i> , 2019, 30, 100504.	0.6	5
76	Immunotherapy as a treatment strategy in advanced stage and recurrent endometrial cancer: review of current phase III immunotherapy clinical trials. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110011.	3.2	5
77	Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study. <i>Gynecologic Oncology</i> , 2022, 164, 428-436.	1.4	5
78	A deficit-accumulation frailty index predicts survival outcomes in patients with gynecologic malignancy. <i>Gynecologic Oncology</i> , 2021, 161, 700-704.	1.4	4
79	Awareness of the association between obesity and peri-operative risk among newly diagnosed patients with complex atypical hyperplasia and endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2015, 12, 41-44.	0.6	3
80	SGO Health Policy and Socioeconomic Committee: Current and Future Efforts of the Coding and Reimbursement Taskforce and the Policy, Quality and Outcomes Taskforce. <i>Gynecologic Oncology</i> , 2016, 143, 229-230.	1.4	3
81	SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth. <i>Gynecologic Oncology</i> , 2018, 151, 337-344.	1.4	3
82	A fellow-run clinic achieves similar patient outcomes as faculty clinics: A safe and feasible model for gynecologic oncology fellow education. <i>Gynecologic Oncology</i> , 2020, 159, 209-213.	1.4	3
83	The role of endometrial sampling for surveillance of recurrence in postmenopausal patients with medically inoperable stage I endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2021, 35, 100694.	0.6	3
84	Inhibition of AXL and VEGF-A Has Improved Therapeutic Efficacy in Uterine Serous Cancer. <i>Cancers</i> , 2021, 13, 5877.	3.7	3
85	The Use of Targeted Agents in the Treatment of Gynecologic Cancers. <i>Current Treatment Options in Oncology</i> , 2022, 23, 15-28.	3.0	3
86	The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancer. <i>BMC Cancer</i> , 2022, 22, 263.	2.6	3
87	Type II endometrial cancers with minimal, non-invasive residual disease on final pathology: What should we do next?. <i>Gynecologic Oncology Reports</i> , 2019, 29, 20-24.	0.6	2
88	Self-reported human papillomavirus vaccination does not have an impact on the risk for high-grade cervical intraepithelial neoplasia among women referred for colposcopy. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 123-126.	1.3	1
89	Reply. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 216, 192-193.	1.3	0
90	Abstract PO045: Inhibition of GAS6/AXL improves efficacy of HER2 inhibitor trastuzumab in uterine serous cancer. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
91	A phase II randomized, double-blind trial of a polyvalent vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian (EOC), fallopian tube, or peritoneal cancer who are in second or third complete remission.. Journal of Clinical Oncology, 2016, 34, 5517-5517.	1.6	0
92	A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus: An NRG/Gynecologic Oncology Group study.. Journal of Clinical Oncology, 2016, 34, 5585-5585.	1.6	0
93	The impact of tumor size and histology on local control when utilizing high-dose-rate interstitial brachytherapy for gynecologic malignancies. Gynecologic Oncology, 2022, , .	1.4	0